Author Topic: Dalfampridine and liver injury research information (PubMed)  (Read 110 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest
Dalfampridine and liver injury research information (PubMed)
« on: November 24, 2019, 03:39:42 pm »

Below is a link to the Overview section of the report from the National Institute of Diabetes and Digestive and Kidney Diseases report, LiverTox: Clinical Research Information on Drug-Induced Liver Injury. The likelihood score for Ampyra (dalfampridine) is E ("unproven although suspected rare cause of clinically apparent liver injury").

https://www.ncbi.nlm.nih.gov/books/NBK548455/#Dalfampridine.OVERVIEW
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
74 Views
Last post October 25, 2019, 07:56:09 pm
by agate
0 Replies
138 Views
Last post October 28, 2019, 04:12:17 pm
by agate
0 Replies
75 Views
Last post November 01, 2019, 06:08:19 pm
by agate
0 Replies
73 Views
Last post November 04, 2019, 02:43:44 pm
by agate
0 Replies
85 Views
Last post February 06, 2020, 08:19:42 pm
by agate